Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


HCFA Coverage and Analysis Group

This article was originally published in The Gray Sheet

Executive Summary

Hugh Hill, MD, will serve as interim acting director for the coverage group, effective immediately following the departure of Grant Bagley, MD, at the end of the month. Hill is a member of the Johns Hopkins University faculty, but currently is serving under a government exchange program as a medical officer in the Health Care Financing Administration's Center for Health Plans and Providers. While Hill was appointed in June by Administrator Nancy-Ann DeParle to chair HCFA's Physician Regulatory Review Issues Team, he has only worked full time at CHPP for the last several months. HCFA intends to mount a nation-wide search for a permanent replacement to Bagley, who recently signed on with the Washington, D.C. law firm Arnold & Porter (1"The Gray Sheet" Nov. 1, p. 4)

You may also be interested in...

HCFA Coverage Group Loses Chief Bagley To Arnold & Porter

A permanent replacement for Coverage and Analysis Group Director Grant Bagley, MD, likely will need to have a medical degree, the Health Care Financing Administration official observed after announcing his departure from the agency the week of Oct. 25.

Finance Watch: Silverback, Kinnate, Sigilon Launch December’s First IPOs

Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.

BioCryst’s Oral Option To Take On Injectables In HAE Prophylaxis Market

Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts